17 results
- To study the clinical characteristics and disease course of patients with LEMS with or without SCLC- To identify the characteristics of the humoral or cellular immune response that are associated with the prolonged survival of patients with SCLC…
The primary objective of this study is to compare PFS with LY2875358 plus erlotinib therapy with erlotinibmonotherapy as first-line treatment in metastatic NSCLC patients with activating EGFR mutations who havedisease control after an 8-week lead-in…
The primary efficacy objective for this study is to evaluate the efficacy of MPDL3280Ain patients with PD-L1*positive locally advanced or metastatic NSCLC, as measuredby investigator-assessed ORR according to modified RECIST.SECONDARY OBJECTIVESThe…
Complete endosonographic (combined endobronchial and esophageal) staging of hilar and mediastinal lymph nodes in patients with (suspected) non-small cell lung cancer (NSCLC) will result in change of loco-regional nodal status in 20% of patients, in…
The primary objective of this study is to estimate the best objective response rates (ORR; complete response [CR] + partial response [PR]) associated with gemcitabine-cisplatin plus necitumumab in chemotherapy-naïve patients with Stage IV squamous…
To study the effect of surgery and SABR on both immunostimulatory (with primary endpoint CD8 positive cells)and immunosuppressive cells in peripheral blood in patients with early stage non-small cell lung cancer who are treated with either modality.
Complete endosonographic (combined endobronchial and esophageal) staging using a single EBUS scope improves locoregional staging (N2, N3, T4) versus EBUS (endobronchial) staging alone.
To evaluate the efficacy of pasireotide LAR and everolimus alone or in combination in progressive patients with a well differentiated neuroendocrine tumor of the lung or thymus.
The primary objective of this study is to evaluate the overall response rate (ORR) of LY2875358 plus erlotinib therapy and LY2875358 monotherapy in patients with met proto-oncogene (hepatocyte growth factor receptor) (MET) diagnostic positive (MET…
To determine the efficacy and safety of adding transdermal nitroglycerin to first line chemotherapy for advanced NSCLC.
This study will investigate if it is possible to perform the EGFR mutation test using blood samples. If successful, this study may mean that in the future, the mutation test can be done using a blood sample, and that patients may not need to have…
To provide continued treatment with trametinib.
1. To define the optimal pharmacokinetic tracer model for [18F]afatinib. 2. To determine the optimal simplified measure for quantifying tumor [18F]afatinib uptake 3. To assess [18F]afatinib uptake differences between patients (1) with wild type EGFR…
1) Objective: To compare the overall survival (OS) of previously-treated subjects with NSCLC in the strongly positive PD-L1 stratum treated with MK-3475 compared to docetaxel.2) Objective: To compare progression-free survival (PFS) per RECIST 1.1 by…
Primary objective:* To evaluate the safety of vaccination with XAGE1B peptides emulsified in Montanide ISA 51 co-mixed with the adjuvant Hiltonol® (Poly-ICLC) in patients with pulmonary adenocarcinoma.Secondary objective* To evaluate the capacity of…
Primary: To compare progression-free survival (PFS) between erlotinib alone and cisplatin-pemetrexed-erlotinib in patients with EGFR mutated NSCLC locally advanced and metastatic disease stage IIIB and IV.Secondary: To characterize toxicities of…
Primary: overall response rate.Secondary: progression free survival, duration of response, overall survival, safety, tolerability, pharmacokinetics (PK).